Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1007/s11523-023-01008-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC
- (2022) Wei Li et al. LUNG CANCER
- Small-cell lung cancer
- (2021) Charles M. Rudin et al. Nature Reviews Disease Primers
- Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study
- (2021) Fiona Blackhall et al. Journal of Thoracic Oncology
- A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer
- (2021) Jyoti Malhotra et al. Journal of Thoracic Oncology
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
- (2021) A.-M.C. Dingemans et al. ANNALS OF ONCOLOGY
- P47.11 DLL-3 and ASCL-1 Expression Emerge as Promising Therapeutic Targets in High-Grade Neuroendocrine Lung Tumors: A Preliminary Study
- (2021) T. Prieto et al. Journal of Thoracic Oncology
- Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study
- (2021) Melissa L. Johnson et al. Journal of Thoracic Oncology
- The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
- (2021) Matthew J. Page et al. International Journal of Surgery
- Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms
- (2021) Greta Alì et al. Frontiers in Oncology
- Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples
- (2021) Christiane Kuempers et al. Frontiers in Medicine
- Immunotherapeutic approaches for small-cell lung cancer
- (2020) Wade T. Iams et al. Nature Reviews Clinical Oncology
- International real-world study of DLL3 expression in patients with small cell lung cancer
- (2020) Federico Rojo et al. LUNG CANCER
- The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy
- (2020) Salomon Tendler et al. PLoS One
- Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis
- (2020) Benchao Chen et al. World Journal of Surgical Oncology
- Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer
- (2020) Jonathan W. Goldman et al. CTS-Clinical and Translational Science
- Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics
- (2019) Richard S. P. Huang et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures
- (2019) Luka Brcic et al. Diagnostic Pathology
- Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)
- (2019) Megumi Furuta et al. ONCOLOGIST
- DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer
- (2019) Jianling Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- DLL3: an emerging target in small cell lung cancer
- (2019) Dwight H. Owen et al. Journal of Hematology & Oncology
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors
- (2019) Hao Xie et al. LUNG CANCER
- Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
- (2019) Hibiki Udagawa et al. LUNG CANCER
- Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment
- (2019) Ippokratis Messaritakis et al. LUNG CANCER
- Current Diagnosis and Management of Small-Cell Lung Cancer
- (2019) Shuhang Wang et al. MAYO CLINIC PROCEEDINGS
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- P2.12-18 Prevalence of DLL3 Expression and Its Prognostic Role in Extensive Stage Small Cell Lung Cancer
- (2019) S. Lim et al. Journal of Thoracic Oncology
- Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer
- (2019) Orgilmaa Regzedmaa et al. OncoTargets and Therapy
- Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
- (2018) Kentaro Tanaka et al. LUNG CANCER
- Identifying treatment options for SCLC patients with multiplexed clinical proteomic testing.
- (2018) Eunkyung An et al. JOURNAL OF CLINICAL ONCOLOGY
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started